MDxHealth SA Ordinary Shares (MDXH) Dividend History

MDxHealth SA is a medical technology company specializing in the development and commercialization of advanced molecular diagnostic tests for the detection and management of prostate and bladder cancers. Leveraging genomic biomarkers, the company aims to enhance personalized treatment decisions and improve patient outcomes in urology.

Website: https://www.mdxhealth.com

Dividend History

MDxHealth SA Ordinary Shares currently does not pay dividends

Company News

Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight

The molecular diagnostics market is experiencing significant growth driven by advancements in technology, increasing demand for personalized medicine, and the rising prevalence of chronic diseases. Innovations such as next-generation sequencing (NGS) and PCR-based testing are expanding the scope of molecular diagnostics, enabling early detection and more accurate diagnoses.

GlobeNewswire Inc.

Featured Companies: A ABT DHR EXAS ILMN MYGN QGEN TMO
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide

The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

GlobeNewswire Inc.

Featured Companies: ADPT AMGN BIO BIO.B BMY DGX EXAS GH GILD ILMN LH MYGN NEO NTRA OPK TECH VCYT
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

mdxhealth reported strong Q4 2024 and full-year 2024 financial results, with 28% revenue growth, improved adjusted EBITDA, and expects to achieve adjusted EBITDA profitability in the first half of 2025.

GlobeNewswire Inc.

Featured Companies: EXAS
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance

MDxHealth reported strong preliminary Q4 and full-year 2024 revenue growth, and issued 2025 revenue guidance of $108-110 million, representing 20-22% year-over-year growth. The company expects to achieve adjusted EBITDA profitability in the first half of 2025.

GlobeNewswire Inc.
Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights

The liquid biopsy market is experiencing significant growth, driven by advancements in technology and increasing demand for non-invasive diagnostic methods. North America is the largest market, with a 48.11% share in 2023. Key drivers include increased benefits over conventional biopsy, rising cancer incidence, and technological advancements, while high costs and shortage of skilled professionals pose challenges.

GlobeNewswire Inc.

Featured Companies: BIO BIO.B CDNA EXAS GH ILMN MYGN NTRA QGEN TMO

Dividend data last updated 06/07/2025 17:03:44 UTC